---
title: Rectal Misoprostol in Women Undergoing Total Abdominal Hysterectomy for Intraoperative Blood Loss Reduction
nct_id: NCT05862428
overall_status: COMPLETED
phase: NA
sponsor: Queen Savang Vadhana Memorial Hospital, Thailand
study_type: INTERVENTIONAL
primary_condition: Intraoperative Blood Loss
countries: Thailand
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05862428.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05862428"
ct_last_update_post_date: 2023-05-17
last_seen_at: "2026-05-12T07:17:46.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Rectal Misoprostol in Women Undergoing Total Abdominal Hysterectomy for Intraoperative Blood Loss Reduction

**NCT ID:** [NCT05862428](https://clinicaltrials.gov/study/NCT05862428)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 56
- **Lead Sponsor:** Queen Savang Vadhana Memorial Hospital, Thailand
- **Conditions:** Intraoperative Blood Loss
- **Start Date:** 2022-02-18
- **Completion Date:** 2022-09-26
- **CT.gov Last Update:** 2023-05-17

## Brief Summary

Comparing of the intraoperative blood loss between group rectal misoprostol group and control group

## Detailed Description

This open-labeled randomized controlled trial was conducted at the Department of Obstetrics and Gynecology, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, from February 2022 to September 2022, after approval of the Institution of Review Board of Queen Savang Vadhana Memorial Hospital (IRB No. 001/2565).

Fifty six (56) women with diagnosis of benign uterine disease who were scheduled to perform total abdominal hysterectomy with or without bilateral salpingo-oophorectomy between February 2022 to September 2022 at Queen Savang Vadhana Memorial Hospital were enrolled in this study.

The participants were randomly allocated into two groups, study and control group. The randomization list was kept in a sealed opaque envelope. Study group received two tablets of 200 mcg misoprostol; The drug was inserted rectally 1 hour before operation. Few drops of normal saline were used to dissolve tablets before insertion. Control group that did not receive the drug. The drug was administered by a nurse at Gynecologic ward. The primary outcome was intraoperative blood loss that recorded by measuring amount of blood on the surgical gauzes and swabs by standardized scales and another was recorded from blood in suction container. The secondary outcome was hemoglobin differentiation, rate of blood transfusion and adverse events of misoprostol usage.

## Eligibility

- **Minimum age:** 20 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Female undergoing total abdominal hysterectomy (elective case) with

* No history of bleeding tendency
* No history of anticoagulant drug used within 7 days before surgery
* No contraindications of Misoprostol drug used
* No history of allergic to misoprostol

Exclusion Criteria:

* Can not communicate with Thai language
* Malignancy case
* Emergency case
```

## Arms

- **Rectal misoprostol** (EXPERIMENTAL) — This group received misoprostol transrectally before surgery 1 hour
- **Control group** (NO_INTERVENTION) — This group not received any drugs before surgery

## Interventions

- **Rectal misoprostol** (DRUG) — This intervention group receive Misoprostol transrectally before undergoing total abdominal hysterectomy

## Primary Outcomes

- **Intraoperative blood loss** _(time frame: 7 months)_ — The intraoperative blood loss was defined as the blood at starting with a cut in the skin until the suture is closed. Its quantity was measure from blood pads and was record in millilitres. One gram of the blood was 1 ml.

## Secondary Outcomes

- **hemoglobin difference** _(time frame: 7 months)_
- **Blood transfusion** _(time frame: 7 months)_
- **Number of participants that have side effects of misoprostol** _(time frame: 7 months)_

## Locations (1)

- Yingdhanai Pannaraj, Chon Buri, Changwat Chon Buri, Thailand

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.yingdhanai pannaraj|chon buri|changwat chon buri|thailand` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05862428.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05862428*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*